Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325–331

Lignende værker

• Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study
  af: Abdul-Ghani, Muhammad, et al.
  Udgivet: (2017)
• Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
  af: Ponirakis, Georgios, et al.
  Udgivet: (2020)
• Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
  af: DeFronzo, Ralph A., et al.
  Udgivet: (2010)
• Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
  af: Triplitt, Curtis, et al.
  Udgivet: (2010)
• Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial
  af: Abdul-Ghani, M. A., et al.
  Udgivet: (2015)